“It is very encouraging that nearly 4 out of 5 people in the survey taking a CGRP monoclonal antibody felt better and reported their migraine had improved,” said Sait Ashina, M.D.,
Patient’s Assessment of Their Migraine After Taking a CGRP mAb for Preventive Treatment
Of the 586 people who reported using a CGRP mAb for the preventive treatment of migraine in the past three months, 79.2% reported perception of their migraine as “better,” 11.3% indicated “no change” and 9.6% said it was “worse.” These findings were relatively consistent across groups: 80.3% (0-3 headache days per month), 80.8% (4-7 headache days per month), 79.8% (8-14 headache days per month) and 74.6% (≥15 headache days per month). Data was obtained from participants in Q4 2019 and represented 2.8% of the 20,782 participants in the
Use of Additional Recommended Migraine Preventive Medication
Among respondents who used a CGRP mAb in the previous 3 months, 62.6% used an additional recommended migraine preventive medication. This finding is consistent with the 2018 position statement of the
“Given the AHS position statement and these exciting results that people reported their migraine as ‘better’ overall after taking novel CGRPs mAbs,
Use of an additional migraine preventive medication was generally higher for patients with more frequent migraine headache days per month: 56.8% (0-3 headache days per month), 64.6% (4-7 headache days per month), 70.9% (8-14 headache days per month) and 70.2% (≥15 headache days per month). Recommended preventive medications for migraine were defined by the guidelines of the
“We are pleased to share the latest insights from OVERCOME, which will enroll 100,000 people with migraine from around the globe and make it the largest population-based study of its kind by including
For additional information, read about
About the OVERCOME Study
The Observational Survey of the Epidemiology, Treatment and Care of Migraine (OVERCOME) study aims to further understand the unmet needs of those with migraine by assessing the burden of migraine experienced by people living with the disease, identify barriers to the appropriate treatment of migraine, and assess how the introduction of novel treatment options may influence delivery of migraine care and outcomes.
OVERCOME is a prospective, web-based patient survey and will enroll 100,000 individuals with migraine from regions across the globe.
- Richard B. Lipton, M.D., (Study Chair),
Department of Neurology, Albert Einstein College of Medicine and Director, Montefiore Headache Center, Montefiore Health System Sait Ashina, M.D., Department of Neurologyand Department of Anesthesia, Critical Care and Pain Medicine, and Harvard Medical School, Beth Israel Deaconess Medical Center Dawn C. Buse, Ph.D., Department of Neurology, Albert Einstein College of Medicine, Clinical Health Psychology Doctoral Program of the Ferkauf Graduate School of Psychology, Yeshiva University Susan Hutchinson, M.D., Orange County Migraine and Headache Center Michael L. Reed, Ph.D., President, Vedanta Research Robert E. Shapiro, M.D., Department of Neurological Sciences, Larner College of Medicine, University of Vermont
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the OVERCOME study and its assessment of the unmet needs of patients with migraine and the use of novel therapies, including the class of CGRP monoclonal antibodies, and reflects
View original content to download multimedia:http://www.prnewswire.com/news-releases/lillys-overcome-study-reveals-nearly-80-of-people-reported-improvement-in-their-migraine-since-starting-a-cgrp-monoclonal-antibody-for-preventive-treatment-301149147.html